Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

This study is testing a radioactive drug called 225Ac-LNC1011 for men with metastatic castration-resistant prostate cancer (mCRPC) — prostate cancer that has spread and keeps growing despite hormone therapy that keeps testosterone at very low levels. **You may be eligible if...** - You have prostate cancer that has spread and is no longer responding to standard hormone therapy - Your PSA levels are rising or your cancer is visibly progressing on imaging - You have either tried and failed standard therapies, refused them, or there are no further standard options available - You are in adequate overall health to tolerate the treatment **You may NOT be eligible if...** - Your cancer is not truly castration-resistant (testosterone is not at castrate levels) - You have serious organ problems (liver, kidney, bone marrow) that would prevent safe treatment - You are unable to follow the radiation safety protocols required during treatment - You have had certain recent treatments that would interfere with this study Talk to your doctor to see if this trial is right for you.